Archive for February 2022
US Patent Granted for Nasodine in COVID-19
Firebrick Pharma’s patent application covering the use of Nasodine® Nasal Spray (Nasodine) in COVID-19 has been granted in the US. The US patent dated 15 February 2022, is titled: “Prevention of infection by highly pathogenic viruses using topical application of povidone-iodine on mucous membranes.” A copy of the patent is available to view on the…
Peter Molloy on the Nasodine SARS-CoV-2 data and the Firebrick vision
“Our goal is to create a successful Australian pharmaceutical business that is globally-facing…and I hope that in the next five years we will see Nasodine sold in most countries around the world.”
Nasodine in vitro and pilot human COVID-19 studies published
The results of in vitro studies of Nasodine® Nasal Spray (povidone-iodine 0.5%) against SARSCoV-2, and a pilot human study in a small number of COVID-19 subjects, have been published in the Australian Journal of Otolaryngology (AJO). The paper titled: “In vivo (human) and in vitro inactivation of SARS-CoV-2 with 0.5% povidone-iodine nasal spray,” can be…
Peter Molloy on Firebrick’s successful ASX debut and plans for Nasodine
“If approved, we believe Nasodine will be the world’s first nasal spray medicine that actually targets the viral cause of the common cold.”
South African trial of Nasodine in COVID-19 receives local approval to proceed
The Company’s planned clinical trial of Nasodine Nasal Spray (povidone-iodine 0.5%) in COVID-19 patients in South Africa, has received approval to proceed from the South African Health Products Regulatory Authority (SAHPRA). The trial is titled: “Reduction of nasal shedding of SARS-CoV-2 in COVID-19 positive patients by the use of Nasodine® (povidone-iodine 0.5%) Nasal Spray.” It…